Supply Chain Tech Stock Could Get a ‘Shot in the Arm’ From the COVID Vaccine Rollout

Tecsys Inc. (TSX:TCS) has the potential to dominate the $600 million health care provide chain administration house

Cash Ideas Media | February 5, 2021 | SmallCapPower: Supply chain management, which makes sure the productive stream of merchandise setting up from accumulating the uncooked supplies all the way to delivery of the final product, has grow to be crucial in our increasingly elaborate worldwide professional ecosystem.

(Originally published on Cash Ideas Media on December 15, 2020)


Canadian company Tecsys Inc. (TSX:TCS) develops and sells enterprise-wide provide chain management application for distribution, warehousing, and transportation logistics, concentrating on principally the North American marketplace.

[Editor’s Note: Shares of Tecsys have climbed 19% since Capital Ideas wrote about the company about six weeks ago.]

[Please click here to get immediate access to curated research in the weekly Capital Ideas Digest with our free 30-Day Trial.] 

The business a short while ago documented far better-than-envisioned Q2 Fiscal 2021 profits that rose 18% calendar year about 12 months to $30.7 million, its seventh consecutive quarterly major-line report. About 63% of its profits all through the past 12 months arrived from the United States and Tecsys has extra than 1000 clients throughout the world.

Recurring revenue, even though, carries on to be the target at Tecsys, as its once-a-year recurring income climbed 26% yr about yr to $50.9 million, which it attributed principally to eCommerce proliferation.

As properly, increased-margin SaaS (computer software as a provider) income continues to be the Company’s fastest-expanding earnings stream (now accounting for 17% of gross sales), with trailing twelve thirty day period SaaS bookings surging 159% from a yr earlier. The Company’s changeover to a SaaS organization model is expected to generate accelerated natural progress.

Tecsys also recorded a second-quarter profit of $2.1 million or $.14 per share, up from $1.4 million, or $.11 for every share, throughout the exact period of time last yr.

Cormark Securities analyst Gavin Fairweather wrote not long ago that Tecsys is owning discussions on opportunity possibilities to offer application to handle the distribution of COVID-19 vaccines.

“Its remedy is compliant with drug offer chain security act needs and can tackle chilly chain deployments. The R&D workforce has also designed a position-of-use software to track the shipping of the vaccine,” he said, incorporating that possible profits from this could be “meaningful.”

Tecsys does have experience in this location, suggests Laurentian Financial institution Securities analyst Nick Agostino, who famous that the Corporation was associated in the H1N1 vaccine rollout in the US above a interval of about a yr in 2009.

Mr. Agostino famous that Tecsys proceeds to investigate M&A possibilities in just the US health care source chain management place, as properly as “expanding its geographical access in Europe and Asia to complement organic progress.” The world-wide healthcare supply chain administration sector is believed to be a $600 million current market chance.

At last, Tecsys traders have benefitted from the Company’s restricted money construction (just 14.4 million shares fantastic), about 26% of which are owned by Company insiders.

To read our full disclosure, be sure to simply click on the button beneath:

The Content contained on this web site (together with any information, sights, opinions, suggestions, description of, or references to, solutions or securities) manufactured readily available by SmallCapPower/Ubika Investigate is for information and facts applications only and is not customized to the wants or circumstances of any individual man or woman. Any mention of a particular protection is basically a general dialogue of the deserves and pitfalls connected there with and is not to be utilised or construed as an offer to promote, a solicitation of an offer to obtain, or an endorsement, recommendation, or sponsorship of any entity or safety by SmallCapPower/Ubika Investigation. The Reader really should use his/her personal judgment in making any use of any Content material, together with, with out limitation, the use of any information contained therein as the foundation for any conclusions. The Reader bears responsibility for his/her possess expenditure analysis and selections. Before generating any investment decision determination, it is strongly advised that you seek outside the house assistance from a qualified financial investment advisor. SmallCapPower/Ubika Investigate does not give or warranty any financial, lawful, tax, or accounting advice or suggestions relating to the suitability, profitability, or opportunity worth of any particular expenditure, stability, or information and facts source. Ubika and/or its affiliate marketers and/or their respective officers, administrators or staff may perhaps from time to time obtain, hold or provide securities and/or commodities and/or commodity futures contracts in certain underlying organizations outlined in this web site and which may perhaps also be clientele of Ubika’s affiliates. In this kind of scenarios, Ubika and/or its affiliate marketers and/or their respective officers, directors or workforce will use all affordable attempts to steer clear of partaking in activities that would lead to conflicts of fascination and Ubika and/or its affiliate marketers will use all sensible attempts to comply with conflicts of interest disclosures and laws to lessen the conflict.